推荐产品
一般說明
Androgen receptor (AR) is a nuclear transcription factor. It belongs to the steroid hormone receptor superfamily. AR gene is located on human chromosome Xq12. AR is present in endothelial and vascular smooth muscle cells.
免疫原
Peptide with sequence EVQLGLGRVYPRPPSC from the N Terminus of the protein sequence according to NP_000035.2.
生化／生理作用
Androgens like testosterone and 5α-dihydrotestosterone are required for the progression, growth, differentiation and maintenance of organ structure of the prostate. It plays a major role in normal and malignant breast tissue.
特點和優勢
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
外觀
Supplied at 0.5 mg/mL in Tris saline with 0.02% sodium azide and 0.5% bovine serum albumin.
免責聲明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品？
试试我们的产品选型工具.
訊號詞
Warning
危險聲明
危險分類
Eye Irrit. 2 - Skin Irrit. 2
儲存類別代碼
10 - Combustible liquids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Androgen receptor expression on circulating tumor cells in metastatic breast cancer.
Fujii T, et al.
PLoS ONE, 12(9), e0185231-e0185231 (2016)
The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity.
Zitzmann M, et al.
The Journal of Clinical Endocrinology and Metabolism, 86(10), 4867-4873 (2001)
FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy.
Kaltz-Wittmer C, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology, 80(9), 1455?1464-1455?1464 (2000)
Melissa A Babcook et al.
Molecular cancer therapeutics, 13(10), 2288-2302 (2014-08-15)
Docetaxel chemotherapy remains a standard of care for metastatic castration-resistant prostate cancer (CRPC). Docetaxel modestly increases survival, yet results in frequent occurrence of side effects and resistant disease. An alternate chemotherapy with greater efficacy and minimal side effects is needed.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门